EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
University of Southern California School of Medicine
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
Cancer Centers of Florida
Orlando, Florida, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
New York Oncology Hematology
Albany, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Mary Crowley Medical Research Center
Dallas, Texas, United States
Tyler Cancer Center
Tyler, Texas, United States
University of Washington
Seattle, Washington, United States
Cancer Care Northwest
Spokane, Washington, United States